Faraday Pharmaceuticals is developing FDY-5301, a therapeutic that utilizes sodium iodide to neutralize hydrogen peroxide during ischemia-reperfusion injury, thereby reducing cardiac damage and inflammation. This approach aims to mitigate the adverse effects of myocardial infarctions and decrease the risk of heart failure in patients undergoing percutaneous coronary intervention.
Funding
Funding not disclosed
Founders
Product
Problem
Myocardial infarctions lead to ischemia-reperfusion injury (IRI), causing cardiac damage and increasing the risk of heart failure. Current treatments often fail to fully address the hydrogen peroxide produced during IRI, resulting in continued tissue damage and inflammation.
Solution
Faraday Pharmaceuticals is developing FDY-5301, an investigational therapeutic that utilizes sodium iodide to neutralize hydrogen peroxide produced during ischemia-reperfusion injury. By targeting IRI, FDY-5301 aims to reduce cardiac damage, inflammation, and infarct size in patients experiencing myocardial infarctions. The product is intended to complement percutaneous coronary intervention (PCI) in the management of ST-elevation myocardial infarction (STEMI).
Target Audience
The primary target audience includes patients experiencing myocardial infarctions, specifically those undergoing percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI).
Features
- Utilizes sodium iodide to neutralize hydrogen peroxide.
- Designed to reduce tissue damage, inflammation, and infarct size.
- Easy-to-administer formulation.
- Currently in Phase 3 clinical trials (Iocyte AMI-3) to assess its potential to reduce heart failure and cardiovascular death among patients suffering from an anterior STEMI.